Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Cerchietti Research Lab
Explore this Website
Home
Research
Toggle Research menu options
Projects
Lab Team
Publications
News
Weill Cornell Medicine
Care
Discover
Teach
Home
Research
Lab Team
Publications
News
Home
Publications
Publications
Found 10 results
Author
Title
Type
Year
Filters:
Author
is
Martin, Peter
[Clear All Filters]
2023
Ruan J
,
Moskowitz AJ
,
Mehta-Shah N
,
Sokol L
,
Chen Z
,
Kotlov N
,
Nos G
,
Sorokina M
,
Maksimov V
,
Sboner A
et al.
. 2023.
Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma.
.
Blood.
2022
Martin P
,
Bartlett NL
,
Chavez JC
,
Reagan JL
,
Smith SM
,
LaCasce AS
,
Jones J
,
Drew J
,
Wu C
,
Mulvey E
et al.
. 2022.
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
.
Blood. 139(8):1147-1159.
2021
M Calvo-Vidal N
,
Zamponi N
,
Krumsiek J
,
Stockslager MA
,
Revuelta MV
,
Phillip JM
,
Marullo R
,
Tikhonova E
,
Kotlov N
,
Patel J
et al.
. 2021.
Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas.
.
Cancer Res. 81(20):5202-5216.
2018
Rutherford SC
,
Stewart EN
,
Chen Z
,
Chadburn A
,
Wehrli NE
,
van Besien K
,
Martin P
,
Furman RR
,
Leonard JP
,
Cerchietti L
. 2018.
The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data
.
.
Leuk Lymphoma. 59(1):256-258.
Ruan J
,
Martin P
,
Christos P
,
Cerchietti L
,
Tam W
,
Shah B
,
Schuster SJ
,
Rodriguez A
,
Hyman D
,
Calvo-Vidal MNieves
et al.
. 2018.
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.
.
Blood. 132(19):2016-2025.
2017
Rutherford SC
,
Stewart EN
,
Chen Z
,
Chadburn A
,
Wehrli NE
,
van Besien K
,
Martin P
,
Furman RR
,
Leonard JP
,
Cerchietti L
. 2017.
The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.
.
Leuk Lymphoma. :1-3.
2016
Pera B
,
Tang T
,
Marullo R
,
Yang S-N
,
Ahn H
,
Patel J
,
Elstrom R
,
Ruan J
,
Furman R
,
Leonard J
et al.
. 2016.
Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.
.
Clin Epigenetics. 8:79.
Dupont T
,
Yang SNing
,
Patel J
,
Hatzi K
,
Malik A
,
Tam W
,
Martin P
,
Leonard J
,
Melnick A
,
Cerchietti L
. 2016.
Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
.
Oncotarget. 7(3):3520-32.
2013
Clozel T
,
Yang SN
,
Elstrom RL
,
Tam W
,
Martin P
,
Kormaksson M
,
Banerjee S
,
Vasanthakumar A
,
Culjkovic B
,
Scott DW
et al.
. 2013.
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
.
Cancer Discov. 3(9):1002-19.
2010
Elstrom RL
,
Martin P
,
Ostrow K
,
Barrientos J
,
Chadburn A
,
Furman R
,
Ruan J
,
Shore T
,
Schuster M
,
Cerchietti L
et al.
. 2010.
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.
.
Clin Lymphoma Myeloma Leuk. 10(3):192-6.